AstraZeneca $39B Acquisition of US biotech Alexion Is Well-Thought Move
As part of the massive $39 billion deal, AstraZeneca has agreed to pay a whopping 45% of the share price of Alexion. As per analysts, this could be a win-win situation for both companies.